Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation

American Journal of Hematology

Volumn 59, Issue 1, 1998, Pages 9-14

  Anthony, Maya T ^a   Zeigler, Zella R ^a,j   Lister, John ^a   Raymond, Jane M ^a,j   Shadduck, Richard K ^a,j   Kramer, Robert E ^b   Gryn, Jeffrey F ^c   Rintels, P B ^d   Besa, Emmanuel C ^e   George, James N ^f   Silver, Bernard ^g   Joyce, Robert ^h   Bodensteiner, David ⁱ  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

^b AMERICAN RED CROSS   (United States)

^c Department of Anesthesiology   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

^e ALLEGHENY UNIVERSITY HOSPITALS   (United States)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h Baptist Regional Cancer Institute   (United States)

ⁱ UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^j North American TIP Group   (United States)

more..

Author keywords

Plasminogen activator inhibitor; TTP; TTP post bone marrow transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISONE; STEROID;

ANTIGEN DETECTION; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEROID THERAPY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 17344375843     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199809)59:1<9::AID-AJH3>3.0.CO;2-T     Document Type: Article

References (25)

1. Byrnes JJ, Moake JL: Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: Evolving concepts of pathogenesis and therapy. Clin Haematol 15:413, 1986.
2. Amorosi EL, Ultmann JE: Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine 45:139, 1966.
3. Rock, GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA: The Canadian Apheresis Study Group: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393, 1991.
4. Remuzzi G, Ruggenenti P: The hemolytic uremic syndrome. Kidney Int 48:2, 1995.
5. Holler E, Kolb HJ, Hiller E, Mraz W, Lehmacher W, Gleixner B, Seeber C, Jehnu Gerhartz HH, Brehm G, Wilmanns W: Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host-disease after HLA-identical bone marrow transplantation. Blood 73:2018, 1989.
6. Rabinowe SN, Soiffer RJ, Tarbell NJ, Neuberg D, Freedman AS, Seifter J, Blake KW, Gribben JG, Anderson KC, Takvorian T, Nadler LM: Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 77:1837, 1991.
7. Pettitt AR, Clark RE: Perspective: Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 14:495, 1994.
8. Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS: Bone marrow transplant-associated thrombotic microangiopathy: A case series. Bone Marrow Transplant 15:247, 1995.
9. Schriber JR, Herzig GP: Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 34:126, 1997.
10. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, Camilla B, Lawton C, Garbrecht F, Gottschall JL: Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 16:271, 1995.
11. Hekman CM, Loskutoff DJ: Fibrinolytic pathways and the endothelium. Semin Thromb Hemost 13:514, 1987.
12. Sprengers ED, Kluft C: Plasminogen activator inhibitors. Blood 69:381, 1987.
13. Bergstein JM, Riley M, Bang NU: Role of plasminogen-activator inhibitor type I in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 327:755, 1992.
14. Chant ID, Milford DV, Rose PE: Plasminogen activator inhibitor activity in diarrhoea-associated haemolytic uraemic syndrome. QJM 87: 737, 1994.
15. van de Kar NC, van Hinsbergh VW, Brommer EJ, Monnens LA: The fibrinolytic system in the hemolytic uremic syndrome: In vivo and in vitro studies. Pediatr Res 36:257, 1994.
16. Menzel D, Levi M, Dooijewaard G, Peters M, ten Cate JW: Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood. Ann Hematol 68:43, 1994.
17. Wada H, Kaneko T, Ohiwa M, Tanigawa M, Hayashi T, Tamaki S, Minami N, Deguchi K, Suzuki K, Nakano S, Shirakawa: Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 44:101, 1993.
18. Declerck PJ, Alessi C, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D: Measurement of plasminogen activator inhibitor I in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71:220, 1988.
19. McGuire TR, Yee GC, Emerson S, Gmur DJ, Carlin J: Pharmacodynamic studies of cyclosporine in marrow transplant recipients. A comparison of three assay methods. Transplantation 53:1272, 1992.
20. Copelan EA, Biggs JC, Szer J, Thompson JM, Crilley P, Brodsky I, Klein JL, Kapoor N, Harman GS, Avalos BR: Allogenoic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Semin Oncol 20(4 Suppl 4):33, 1993.
21. Gonzales-Chambers R, Przepiorka D, Shadduck RK, Borochovitz D, Bloom EJ, Colvin OM, Mangan KF, Rosenfeld CS: Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow for acute lymphoblastic leukemia. Med Pediatr Oncol 19:160, 1991.
22. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RS, Spasoff RA: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393, 1991.
23. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K: Immunohistochemistry of vascular lesions in thrombotic thrombocytopenic purpura with special reference to factor VIII related antigen. Thromb Res 38:469, 1985.
24. Kwaan HC, Gallo G, Potter E, Cutting H, Stanzler R: The nature of the vascular lesion in thrombotic thrombocytopenic purpura. Ann Int Med 68:1169, 1968.
25. Kwaan HC: The pathogenesis of thrombotic thrombocytopenic purpura. Semin Thromb Hemost 5:184, 1979.